mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Wilfredo F Garcia-Beltran; Kerri J St Denis; Angelique Hoelzemer; Evan C Lam; Adam D Nitido; Maegan L Sheehan; Cristhian Berrios; Onosereme Ofoman; Christina C Chang; Blake M Hauser; Jared Feldman; Alex L Roederer; David J Gregory; Mark C Poznansky; Aaron G Schmidt; A John Iafrate; Vivek Naranbhai; Alejandro B Balazs

doi:10.1016/j.cell.2021.12.033

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Cell. 2022 Feb 3;185(3):457-466.e4. doi: 10.1016/j.cell.2021.12.033. Epub 2022 Jan 6.

Authors

Wilfredo F Garcia-Beltran¹, Kerri J St Denis², Angelique Hoelzemer³, Evan C Lam², Adam D Nitido⁴, Maegan L Sheehan², Cristhian Berrios⁵, Onosereme Ofoman⁵, Christina C Chang⁶, Blake M Hauser², Jared Feldman⁴, Alex L Roederer⁴, David J Gregory⁷, Mark C Poznansky⁸, Aaron G Schmidt², A John Iafrate⁵, Vivek Naranbhai⁹, Alejandro B Balazs¹⁰

Affiliations

¹ Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: wgarciabeltran@mgh.harvard.edu.
² Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
³ First Department of Internal Medicine, Division of Infectious Diseases, University Medical Centre Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Site Hamburg-Lübeck-Borstel-Riems, Germany; Research Department Virus Immunology, Leibniz Institute for Experimental Virology, Hamburg, Germany.
⁴ Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Ph.D. Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.
⁵ Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
⁶ Alfred Hospital, Central Clinical School, Monash University, Victoria 3181, Australia; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa.
⁷ Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Pediatric Infectious Disease, Massachusetts General Hospital for Children, Boston, MA 02114, USA.
⁸ Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
⁹ Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
¹⁰ Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: abalazs@mgh.harvard.edu.

Abstract

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild-type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that received their primary series recently (<3 months), distantly (6-12 months), or an additional "booster" dose, while accounting for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinees. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron, only 4-6-fold lower than wild type, suggesting enhanced cross-reactivity of neutralizing antibody responses. In addition, we find that Omicron pseudovirus infects more efficiently than other variants tested. Overall, this study highlights the importance of additional mRNA doses to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.

Keywords: COVID-19; Delta; Omicron; SARS-CoV-2; breadth; infectivity; neutralizing antibodies; spike; vaccination; variants.

Abstract

Grants and funding